Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer.

Sjöberg E, Meyrath M, Milde L, Herrera M, Lövrot J, Hägerstrand D, Frings O, Bartish M, Rolny C, Sonnhammer E, Chevigné A, Augsten M, Östman A.

Clin Cancer Res. 2019 Jun 15;25(12):3702-3717. doi: 10.1158/1078-0432.CCR-18-1294. Epub 2019 Mar 8.

PMID:
30850359
2.

Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing.

Bartoschek M, Oskolkov N, Bocci M, Lövrot J, Larsson C, Sommarin M, Madsen CD, Lindgren D, Pekar G, Karlsson G, Ringnér M, Bergh J, Björklund Å, Pietras K.

Nat Commun. 2018 Dec 4;9(1):5150. doi: 10.1038/s41467-018-07582-3.

3.

A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis.

Sjöberg E, Frödin M, Lövrot J, Mezheyeuski A, Johansson M, Harmenberg U, Egevad L, Sandström P, Östman A.

Br J Cancer. 2018 Oct;119(7):840-846. doi: 10.1038/s41416-018-0266-8. Epub 2018 Oct 8.

PMID:
30293996
4.

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.

Matikas A, Lövrot J, Ramberg A, Eriksson M, Lindsten T, Lekberg T, Hedenfalk I, Loman N, Bergh J, Hatschek T, Erlandsson A, Foukakis T.

Oncoimmunology. 2018 Jul 26;7(9):e1466017. doi: 10.1080/2162402X.2018.1466017. eCollection 2018.

5.

Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.

Sim S, Lövrot J, Lindh JD, Bergh J, Xie H.

Pharmacogenomics. 2018 Aug 1;19(13):1027-1037. doi: 10.2217/pgs-2018-0089. Epub 2018 Jul 19.

PMID:
30022682
6.

Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes.

Ullah I, Karthik GM, Alkodsi A, Kjällquist U, Stålhammar G, Lövrot J, Martinez NF, Lagergren J, Hautaniemi S, Hartman J, Bergh J.

J Clin Invest. 2018 Apr 2;128(4):1355-1370. doi: 10.1172/JCI96149. Epub 2018 Feb 26.

7.

Immune gene expression and response to chemotherapy in advanced breast cancer.

Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N, Suzuki C, Brage SE, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Fernö M, Skoog L, Bergh J, Hatschek T.

Br J Cancer. 2018 Feb 20;118(4):480-488. doi: 10.1038/bjc.2017.446. Epub 2018 Jan 25.

8.

Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.

Karthik GM, Rantalainen M, Stålhammar G, Lövrot J, Ullah I, Alkodsi A, Ma R, Wedlund L, Lindberg J, Frisell J, Bergh J, Hartman J.

BMC Cancer. 2017 Nov 29;17(1):802. doi: 10.1186/s12885-017-3815-2.

9.

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.

Palazon A, Tyrakis PA, Macias D, Veliça P, Rundqvist H, Fitzpatrick S, Vojnovic N, Phan AT, Loman N, Hedenfalk I, Hatschek T, Lövrot J, Foukakis T, Goldrath AW, Bergh J, Johnson RS.

Cancer Cell. 2017 Nov 13;32(5):669-683.e5. doi: 10.1016/j.ccell.2017.10.003.

10.

Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.

Ma R, Karthik GM, Lövrot J, Haglund F, Rosin G, Katchy A, Zhang X, Viberg L, Frisell J, Williams C, Linder S, Fredriksson I, Hartman J.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-14. doi: 10.1093/jnci/djw236.

11.

mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.

Karthik GM, Ma R, Lövrot J, Kis LL, Lindh C, Blomquist L, Fredriksson I, Bergh J, Hartman J.

Cancer Lett. 2015 Oct 10;367(1):76-87. doi: 10.1016/j.canlet.2015.07.017. Epub 2015 Jul 21.

PMID:
26208432
12.

Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer.

Cunha SI, Bocci M, Lövrot J, Eleftheriou N, Roswall P, Cordero E, Lindström L, Bartoschek M, Haller BK, Pearsall RS, Mulivor AW, Kumar R, Larsson C, Bergh J, Pietras K.

Cancer Res. 2015 Jun 15;75(12):2445-56. doi: 10.1158/0008-5472.CAN-14-3706. Erratum in: Cancer Res. 2016 Oct 15;76(20):6131-6132.

13.

Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.

Foukakis T, Lövrot J, Sandqvist P, Xie H, Lindström LS, Giorgetti C, Jacobsson H, Hedayati E, Bergh J.

Mol Oncol. 2015 Aug;9(7):1384-91. doi: 10.1016/j.molonc.2015.03.011. Epub 2015 Apr 3.

14.

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival.

Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group.

Ann Oncol. 2015 Jan;26(1):81-8. doi: 10.1093/annonc/mdu498. Epub 2014 Oct 31.

15.

Thyroid hormone inactivation in gastrointestinal stromal tumors.

Foukakis T, Lövrot J, Bergh J.

N Engl J Med. 2014 Jul 3;371(1):84-5. doi: 10.1056/NEJMc1405198. No abstract available.

PMID:
24988574

Supplemental Content

Loading ...
Support Center